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1ABSTRACT
Immunotoxicity of Zinc Oxide (ZnO) Nanoparticles (NPs)
in vitro and in vivo
Hai-Duong Thi Nguyen
Dept. of Medicine
The Graduate School
Yonsei University
While Zinc Oxide (ZnO) nanoparticle (NP) has been recognized to have 
promising applications in biomedicine, its immunotoxicity has been inconsistent
and even contradictory. To address this issue, we investigated whether ZnO NPs 
with different sizes (20 nm or 100 nm) and electrostatic charges (negative or 
positive) would cause immunotoxicity in vitro and in vivo, and explored their 
underlying molecular mechanism. Using Raw 264.7 cell line, we examined cell 
viability, reactive oxygen species (ROS) generation, mitochondrial membrane 
potential (MMP), and antioxidant enzyme activity to explore the immunotoxicity 
2mechanism of ZnO NPs in vitro. We found that in cell viability assay (CCK-8, 
real-time xCelligence) ZnO NPs with different size and charge could induce 
differential cytotoxicity to Raw 264.7 cells. Specifically, the positively charged 
ZnO NPs exerted higher cytotoxicity than the negatively charged one. Molecular 
study to unravel the mechanism of immune cell toxicity showed that overall, 
treatment of ZnO NPs decreased MMP, generated intracellular ROS, and 
reduced antioxidant enzyme activity such as glutathione peroxidase (GPx). Next,
to gauge systemic immunotoxicity, we assessed immune responses of C57BL/6 
mice after orally administration of sub-lethal dose of ZnO NPs for two weeks. 
Oral intake of ZnO NPs significantly decreased body weight gain. In parallel, 
ZnO NPs did not alter the cell-mediated immune response in mice but 
suppressed innate immunity such as NK cell activity. The CD4+/CD8+ ratio was 
slightly reduced which implies the alteration of immune status induced by ZnO
NPs. Accordingly, nitric oxide (NO) production from splenocyte culture 
supernatant in ZnO NP-fed mice was lower than control. Consistently, serum 
levels of pro/anti-inflammatory (IL-1, TNF-α, and IL-10) and Th1 cytokines 
(IFN-γ, IL-12) in ZnO NP-fed mice were significantly suppressed. Collectively, 
our results indicate that different sized- and charged-ZnO NPs would cause in 
vitro and in vivo immunotoxicity, of which nature is a minor immunosuppression.
This has important implications for individuals who may be chronically exposed 
to ZnO NPs.
Key words: ZnO NPs, immunotoxicity, ROS, immunosuppression, size, charge.
3I. INTRODUCTION
Nanotechnology has enabled NPs to be designed at the molecular 
(nanometer) level. Thus, NPs have received the tremendous advantage of their 
small size, novel physicochemical properties as well as their interactions with 
biological systems. In particular, inorganic NPs with metal oxides have been 
preclinically employed for the diagnostic and the therapeutic use in biomedicine 
(Duguet et al. 2006, 157-68, Salata 2004, 3, Sanvicens, and Marco 2008, 425-33, 
Zhang et al. 2008, 761-9).  Of these metal oxides, ZnO NPs have received 
considerable attention with a promising biological application for drug delivery 
and cancer therapy (De Jong, and Borm 2008, 133-49, Hanley et al. 2008, 
295103, Zhang et al. 2011, 1906-14) due to their great photocatalytic and photo-
oxidizing ability against chemical and biological species.
Despite the potential bio-medical application of ZnO NPs, biohazards 
and toxicities of ZnO NPs remained unclear. Of these toxicities, the effects of 
ZnO NPs on immune system are poorly documented.  Here, immunotoxicity is 
defined as the adverse effects on immune system such as hypersensitivity, 
chronic inflammation, immunosuppression, immunostimulation, and 
autoimmunity. Many evidences suggested that ZnO NPs would function as 
immunotoxicants (Hooper et al. 2011, 1111-7, Jang, Lim, and Choi 2010, 85-91, 
Matsumura et al. 2010, 232-7, Pasupuleti et al. 2011). ZnO NPs have unique 
physiochemical properties, therefore, they could easily access several immune 
tissues and cells through various routines such as inhalation, ingestion, skin 
uptake, and injection. ZnO NP oral administration could cause severe damages in 
heart, lung, liver, and kidney (Zheng, Li, and Wang 2009, 1566-1571), 
4consequently leading to complicated inflammation. Likewise, profuse release of  
inflammatory mediators induced by ZnO NPs (Heng et al. 2011, 1517-28, Roy et 
al. 2011, 110-1) may result in immune stimulation or aggravation of immune 
diseases (Yanagisawa et al. 2009, 314-22), or even break down Th1/Th2 balance 
(Liu et al. 2009, 3934-3945). 
It is well known that immunotoxicity of NPs were intimately linked to 
oxidative stress.  For instance, the toxicity of ZnO NP to immune cells was 
involved in ROS generation (Hanley et al. 2009, 1409-1420, Heng et al. 2010, 
1762-6, Lipovsky et al. 2011, 105101, Song et al. 2010, 389-97). The high 
production of super oxide in mitochondrial reduced the mitochondrial membrane 
potential (Moos et al. 2010, 733-9), caused cell cycle arrest at S/G2 phase 
(Sasidharan et al. 2011, 3657-69), and increased the ratio of Bax/Bcl2 leading to 
mitochondria mediated pathway involved in apoptosis (Sharma, Anderson, and 
Dhawan 2012). But, the mechanism of immunotoxicity of ZnO NPs in relation to 
oxidative stress is unclear. 
To trigger immunotoxicity, several traits of NPs such as size, shape, 
electrostatic charge are very essential (Di Gioacchino et al. 2011, 65S-71S). 
Emerging evidences implied that the toxicity of ZnO NPs could be affected by 
size and/or electrostatic charge (Sohaebuddin et al. 2010, Sun, Zhao, and 
Lombardi 2007, Yang et al. 2009, 69-78). For instance, increase of ZnO NPs size 
might conversely decrease their toxicities (Hanley et al. 2009, 1409-20, 
Padmavathy, and Vijayaraghavan 2008). Positively charged NPs could exert 
higher immnunotoxicity than negatively charged NPs due to effective interaction 
with negative charge of acidic acid on surface of macrophage (P. D. Dwivedi et 
5al., 2009). However, these studies failed to address whether the immunotoxicity 
of ZnO NPs would be affected by the size and/or charge, if so, its 
immunotoxicity is immunostimulatory or immunosuppressive. 
In this study, we explored the in vitro potential immunotoxicity of ZnO 
NP on Raw 264.7 cells, and the systemic in vivo immunotoxicity of ZnO NPs 
using C57BL/6 mice. Further, we investigated the role of size and charge in ZnO 
NP-induced immunotoxicity.
6II. MATERIALS AND METHODS
1. In vitro experiment
1.1. Reagents
ZnO-310 was purchased from Sumitomo Osaka Cement Co. Ltd (Tokyo,
Japan). Zn-OX-01-NP.100N was purchased from Amerian Elements (Los 
Angeles, USA). Dulbecco’s Modified Eagle’s Medium (DMEM), and fetal 
bovine serum (FBS) were obtained from Hyclone Laboratories, Inc. (South 
Logan, USA). Cell Counting Kit-8 (CCK-8) was from Dojindo Molecular 
Technologies, Inc. (Rockville, USA). Peroxide-sensitive fluorescent probe, 2,7-
dichlorodihydrofluorescein diacetate (H2DCFDA) was purchased from Sigma 
Chemical Co. (St Louis, USA). 5,5’,6,6’-tetrachloro-1,1’,3,3’ 
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) was from Molecular Probes 
Inc. (Eugene, USA). SOD and GPx kit were from Biovision Inc. (Mountain 
View, USA). The normal physiological salt solution (NPSS) used throughout this 
study had the following composition (in mM) 125 NaCl, 4.7 KCl, 1.2 KH2PO4, 
1.2 MgSO4, 2.5 CaCl2, 18 NaHCO3, 0.026 Na2EDTA, and 11.2 Glucose. 
1.2. Characterization and preparation of ZnO NPs
The ZnO NPs used in this study were sized at 20 nm (ZnO-310, 
Sumitomo Osaka Cement Co. Ltd, Tokyo, Japan) and 100 nm (Amerian 
Elements, Los Angeles, USA) with approximately 99.5% purity, milky white 
color, nearly spherical shape. In brief, 20 mg dry powder of ZnO NPs was 
dissolved into 100 ml L-Serine/HEPES pH 6.2, and Citrate/HEPES pH 7.3 to 
make NP surface electrostatic charge. Indicated buffers were made as follows: 
for the positive charge buffer, 99 ml of 20 mM HEPES pH 6, L-Serine (1 g) 
adjusted to pH 6.2, and for the negative charge buffer, 99 ml of 20 mM HEPES 
7pH 7, Sodium Citrate (1 g) adjusted to pH 7.3. Subsequently, the ZnO NP 
suspension was vortexed for 5 min at room temperature then kept in 4 oC up to 
use. Before using the suspension was sonicated at 4 oC for 10 min with a 
sonicator (Hielscher-Ultrasound Techonolgy, Teltow, Germany).
1.3. Cell culture 
Raw 264.7, mouse macrophage cell line (American Type Cell Culture 
Collection) was maintained in DMEM (Hyclone Laboratories, Inc., South Logan, 
USA) supplemented with 10% heat-activated fetal bovine serum (FBS, Hyclone 
Laboratories Inc., South Logan, USA) and 1% Antibiotic-Antimycotic (Gibco, 
Invitrogen Corporation, Auckland, N.Z) at  37 oC in 5% CO2 incubator.
1.4. CCK-8 cell viability assay
A commercial available cell viability assay Cell Counting Kit-8 (CCK-8, 
Dojindo Molecular Technologies, Inc., Rockville, USA) was employed to 
evaluate the cytotoxic effect of ZnO NPs. Approximately 1x105 of Raw 264.7 
cells were seeded into each well of 96-well plates then incubated with various 
concentration of ZnO NPs for 24 h at 37 oC in a 5 % CO2 incubator. Afterwards, 
10 μl of CCK-8 solution was added to each well, incubated for 1 h, and then 
absorbance was determined at 450 nm by a DTX-880 multimode microplate 
reader (Bechman Counter Inc., Fullerton, USA).
1.5. Impedance real-time cell viability (xCelligence)
Impedance real-time cell viability was measured using xCelligence 
(ACEA Biosciences, San Diego, USA). Approximately 1x104 of Raw 264.7 cells 
were seeded into each well of 16-well electronic plates (E-Plate 16) to allow 
attachment and growth on the sensor of the E-Plate 16. ZnO NPs were prepared 
in DMEM and added into wells containing cells. Thereafter, the sensor devices 
8were mounted back to device stations placed inside a CO2 incubator. Cell index 
(CI) was automatically recorded every 15-20 min continuously for 96 h by the 
RT-CES system to produce time dependent response dynamic curves. 
1.6. Detection of intracellular reactive oxygen species (ROS)
The generation of intracellular reactive oxygen species (ROS) was 
monitored with peroxide-sensitive fluorescent probe, 2,7-
dichlorodihydrofluorescein diacetate (H2DCFDA) (Sigma Chemical Co., St. 
Louis, USA) according to the manufacture’s guideline. Briefly, Raw 264.7 cells 
were seeded at approximately 2x104 cells per well in 96 well black plates for 12 
h before treatment. Thereafter, cells were treated with 20 μg/ml of ZnO NPs for 
different indicated times (0.5, 1, 3, 6, 24 h) then washed with NPSS and loaded 
with 10 μM of H2DCF-DA (Sigma Chemical Co., St Louis, USA) from a stock 
solution in DMSO. After a 30 min loading at 37 oC in dark incubator, cells were 
washed again with NPSS to remove extra H2DCFH-DA, and immediately 
measured at an excitation wavelength of 485 nm and an emission wavelength of 
530 nm using a DTX-880 multimode microplate reader (Bechman Counter Inc., 
Fullerton, USA).
1.7. Detection of changes in mitochondrial membrane potential (MMP)
Mitochondrial membrane potential (MMP) was determined using the 
lipophilic cationic probe: 5,5’,6,6’-tetrachloro-1,1’,3,3’ 
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) (Molecular Probes Inc., 
Eugene, USA). Briefly, Raw 264.7 cells were seeded at approximately 2x104
cells per well in 96 well black plates for 12 h before treatment. Thereafter, cells 
were treated with 20 μg/ml of ZnO NPs for 3 h, washed once with NPSS, then 
loaded with 5 μM of JC-1 at 37 oC for 20 min. Cells were rinsed in NPSS twice 
9and assayed using a fluorescence spectrometer (Flex Station II 384, Molecular 
Devices Corp., Sunnyvale, USA). The fluorescence ratio (590 to 530 nm) was 
used for quantitative analysis.
1.8. Detection of changes in antioxidant enzyme activity
Activity of superoxide dismutase (SOD) and glutathione peroxidase 
(GPx) were measured using BioVision kit (Mountain View, USA). Briefly, Raw 
264.7 cells were seeded at approximately 1x106 cells per dish in 60 mm dishes 
and treated with 20 μg/ml of ZnO NPs for 3 h. After treating, the cells were 
washed once with PBS, scraped, lysed, and then centrifuged at 12,000 rpm for 
15 min at 4 oC. The supernatant (cell lysate) was removed and the protein 
concentration was measured by the Bradford method. The activities of different 
antioxidant enzymes were then measured in the cell lysates following the 
instruction of the manufacturer.
2. In vivo experiment
2.1. Reagents
Lactase dehydrogenase (LDH) release cytotoxic assay, Griess reagent-
G2930 were obtained from Promega Corp. (Madison, USA). Concanavaline A 
(ConA), lipopolysaccharide (LPS, derived from Salmonella typhosa), Hank’s 
balanced salt solution (HBSS), and trypan blue were purchased from Sigma-
Aldrich Co. (St. Louis, USA). Park Memorial Institute (RPMI) 1640 medium 
was obtained from Hyclone Laboratories, Inc. (Utah, USA). All monoclonals 
(CD4, CD8, CD19, B220, CD16, CD14, CD11) were purchased from BD 
Bioscience (San Diego, USA).
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2.2. Maintenance of animals and ZnO NP treatment
Six-week-old inbred C57BL/6 mice (Orient Bio Co. Ltd., South Korea) 
were maintained in a pathogen-free condition, fed with a standard commercial 
diet. Mice were randomly assigned into five groups: negative control which was 
PBS treated, and four experimental groups were treated with four types of ZnO 
NPs. Briefly, ZnO NP suspension was orally administered into the mice with the 
dosage of 750 mg/kg every day continuously for 14 days. Mouse body weight 
was calculated every day. All experiments were performed according to the 
Animal Ethic Guidelines and were approved by the Institutional Animal Care 
and Use Committee (IACUC) at Wonju College of Medicine, Yonsei University, 
Wonju city, Kangwon province, South Korea.
2.3. Coefﬁcient of spleen to body weight
Spleen was removed aseptically after sacrifice and weighed. The 
coefﬁcient of spleen to body weight was calculated as the ratio of tissues (wet 
weight, mg) to body weight (BW) (g).
2.4. Induction and evaluation of delayed-type hypersensitivity (DTH)
Delayed-type hypersensitivity assays were performed 4 days before 
sacrifice. To assess DTH response, mice were subcutaneously injected left 
footpad with 20 ul of Saline as a control, and into right footpad with 20 μl of 
ZnO NPs suspension. At the indicated times after challenge (24 h and 48 h), 
footpad thickness was measured with a digital caliper (Mitutoyo Corporation, 
Tokyo, Japan). The level of the DTH response was determined as the difference 
between the left and right footpad.
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2.5. Preparation of splenocytes
To isolate splenocytes, the spleen was removed aseptically from 
C57BL/6 mouse at the end point treatment and placed in Hank’s balanced salt 
solution (HBSS, Sigma Chemical Co., St. Louis, USA). Splenocyte suspensions 
were prepared by gently pressing the spleen between the frosted ends of two 
sterile microscope slides into a 90 mm Petri dish. The slides were washed with 
RPMI-1640 medium (Hyclone Laboratories, Inc., South Logan, USA). Cell 
suspension were filtered by a sterile plastic strainer then centrifuged at 1500 rpm
for 3 min. Thereafter, the cell pellets were washed three times in PBS and 
resuspended in RPMI-1640 supplemented with 3 % fetal bovine serum (FBS, 
Hyclone Laboratories Inc., South Logan, USA). The viability of the cells used in 
all experiments was always higher than 85%, as measured by trypan blue 
exclusion (Sigma Chemical Co., St Louis, USA).
2.6. Splenocyte proliferative responses to concanavalin A, and 
lipopolysaccharide
Splenocytes were seeded at 1x105 cells per well into 96 well-flat-
bottom-plate in 100 µl RPMI-1640 (Hyclone Laboratories, Inc., South Logan, 
USA) supplemented with 10% heat-activated FBS (Hyclone Laboratories Inc., 
South Logan, USA) and 1% antibiotic/antimycotics. Thereafter, concanavalin A 
(ConA, Sigma-Aldrich Co., St. Louis, USA) with 4 different concentrations (10, 
5, 2.5, and 1.25μg/ml), or 100 μg/ml of lipopolysaccharide (LPS, Sigma-Aldrich 
Co., St. Louis, USA) were utilized. The plates were incubated at 37 oC in a 
humidified atmosphere under 5% CO2 for 48 h. Cell proliferation was evaluated 
using a CCK-8 kit (Dojindo Molecular Technologies, Inc., Rockville, USA).
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2.7. Cytotoxicity assay of natural killer (NK) cells
Splenocytes (effector cells) were plated into 96 well-flat-bottom plates 
at 105 cells/well in 100 μl RPMI-1640 (Hyclone Laboratories, Inc., South Logan, 
USA). YAC-1 cells (target cells, American Type Cell Culture Collection, 
Manassaas, VA) were subcultured in RPMI-1640 medium supplemented with 10% 
FBS. After 24 h, splenocytes were incubated with YAC-1 at appropriate 
concentrations to obtain effector: target ratios of 100:1; 50:1; 25:1 for 6 h at 37 
oC in atmosphere containing 5% CO2. The cytotoxic activity of NK cells was 
assessed by a LDH release cytotoxic assay (Promega Corp., Madison, USA). 
LDH was assayed in the supernatant by optical density (OD) measurement at 490 
nm. Target cell lysis was calculated as: (OD of sample – OD with spontaneous 
release of LDH from target cells – OD with spontaneous release of LDH from 
effector cells) x 100/(OD with maximal release of LDH from target cells – OD 
with spontaneous release of LDH from target cells).
2.8. Immunophenotyping of splenocytes
Specific leukocyte subtypes of cells derived from mouse spleen were 
also determined by immunofluorescent antibody staining and analyzed with flow 
cytometry. Lymphocyte subpopulations were identified and gated using forward 
versus side scatter characteristics. All monoclonals were directly conjugated and 
were obtained from BD Bioscience (San Diego, USA). T cells (CD4, CD8), B 
cells (CD19, B220), NK cells (CD16) and monocytes (CD14, CD11) were 
identified using the anti-mouse antibodies. Thereafter, approximately 3-5x103
cells were resuspended in flow cytometry buffer (2% FBS, 0.02% sodium azide
in PBS) containing Fc-block to reduce non-specific antibody binding. Cells were 
then incubated in the dark with the appropriate fluorochrome-conjugated 
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antibody (10 μl) for 30 min at 4 oC. Afterwards, cells were washed twice with 
500 μl FACS (Fluorescence Activated Cell Sorter) buffer and flow cytometry 
analysis was performed on the FACS Calibur system (BD Biosciences, Franklin 
Lakes, USA). Control samples were matched for each fluorochrome. Data were 
analyzed using CellQuest software (BD Biosciences, Franklin Lakes, USA).
2.9. Measurement of nitric oxide (NO)
NO production in the primary splenocyte culture medium was 
quantified spectrophotometrically using the Griess reagent- G2930 (Promega 
Corp., Madison, USA). The absorbance at 540 nm was measured, and the NO
concentration was determined using a calibration curve with sodium nitrite as a 
standard chemical.    
2.10. Measurement of serum cytokine level
Level of the cytokines (IL-1β, IL-6, TNF-α, IFN-γ, IL-12p70, and IL-10)
in serum was determined using Multiplex Bead Array System (Bio-Rad, 
Hercules, USA). The cytokine multiplex bead array kit was purchased from Bio-
Rad, San Diego, CA, USA and used according to the manufacturer's 
specifications. Data acquisition and analysis were carried out on 5-parameter 
logistic method.
3. Statistical analysis
All data are presented as the mean ± SEM. The mean values among different 
groups were analyzed and compared using one-way analysis of variance 
(ANOVA) followed by subsequent multiple comparison test (Tukey) with Graph 
Prism version 5.0 software packages (Graph Pad software, La Jolla, USA). One 
way ANOVA with repeated measurements followed by Tukey’s test was applied 
to test the influence of ZnO NPs on body weight gain. Statistical significance 
levels were defined at p < 0.05.
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III. RESULTS
1. ZnO NP preparation
1.1. Dispersion tests
Nanoparticles (NPs) specifically, due to their high specific surface area 
compared to large particles, usually form agglomerates or aggregates,
furthermore, they can be readily precipitated when dispersed in aqueous solution. 
The dispersion behaviors of ZnO NPs were examined in PBS pH 7.4, L-
Serine/HEPES pH 6.2 and Citrate/HEPES pH 7.3 conditions. As shown in Figure 
1, PBS pH 7.4 was not determined to be effective in dispersing ZnO NPs and 
required more extensive mixing. In contrast, L-Serine/HEPES pH 6.2, and 
Citrate/HEPES pH 7.3 exhibited higher dispersion homogeneity of ZnO NPs 
than PBS pH 7.4. We found that the optimum physical mixing method in our 
experiments is simple vortexing for 5 min, followed by the ultra-sonication with 
a probe sonicator for 10 sec. To prevent reagglomeration, ZnO NP stock solution 
was prepared just before the experiment. The working ZnO NP suspension with 
four different concentrations (5, 10, 20, 40 μg/ml) was prepared in cell culture 
media (DMEM). The turbidity of working solution was increased by the 
increment of ZnO NP concentration.
Figure 1. Digital images of ZnO NPs in three different aqueous solutions (PBS 
pH 7.4, L-Serine/HEPES pH 6.2, Citrate/HEPES pH 7.3), and ZnCl
7.4 before (a) and after (b) mixing with vortex for 5 min.
b
a
15
2 in PBS pH 
16
1.2. Physicochemical characterizations of ZnO NPs
The pristine ZnO NPs were determined to have an average particle size 
of ~ 20 and ~ 70 nm, respectively, with homogeneous distribution (Fig. 2a and d). 
We could observe distinct grain boundaries in each SEM images which means 
that the present NPs do not form significant aggregates. The ZnO NPs dispersed 
in either Serine/HEPES pH 6.2 or Citrate/HEPES pH 7.3 also showed similar 
average particle size and homogeneity in distribution (Fig. 2b, c, e and f). The 
grain boundaries of ZnO NPs dispersed in either Serine/HEPES pH 6.2 or 
Citrate/HEPES pH 7.3 is rather blurred compared to that of pristine ones, which 
is attributed the organic moieties (serine or citrate)  coated on the surface of NPs, 
however, we could not observe significant agglomerate formation in those NPs.
Figure 2. Scanning electron microscopic images of ZnO NPs
ZnO20 (b) ZnO20 dispersed in Serine/HEPES pH 6.2 (c) ZnO
Citrate/HEPES pH 7.3 (d) pristine ZnO
pH 6.2 and (f) ZnO70 dispersed in Citrate/HEPES pH 7.3.
17
(a) pristine 
20 dispersed in 
70 (e) ZnO70 dispersed in Serine/HEPES 
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2. In vitro immunotoxicity
Multitude studies suggested that ZnO NP exposure to eukaryotic cells 
would generate ROS in corresponding cells, thereby leading to cellular damage 
or even cell death. However, the influence of ZnO NP size and charge on 
immune cell remains unclear. To clarify this, using four type of ZnO NPs, we 
examined cell viability (end-point, and real time assay), the level of intracellular 
reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and 
antioxidant enzyme activities such as superoxide dismutase (SOD), glutathione 
peroxidase (GPx) in macrophage cell line, Raw 264.7cells.
2.1. End-point cell viability
The effect of ZnO NPs on the viability of Raw 264.7 cells was 
examined using CCK-8 assay (Fig. 3). ZnO NPs at the concentrations 0-5 μg/ml
had minimal effect on the viability of Raw 264.7 cells, although it significantly 
reduced the viability at higher concentration range (10-80 μg/ml) after 24 h 
incubation. To compare the potency of each ZnO NP, EC50 value was calculated
according to sigmoidal dose-response regression (Tab. 1). ZnCl2 was used as a 
positive control. Of note, ZnCl2 was less cytotoxic than ZnO NPs (EC50 = 14.34 
μg/ml). The range of EC50 of ZnO NPs was 7.591-10.37 μg/ml: ZnO 100(+) 
exerted the highest cytotoxicity against Raw 264.7 cells (EC50 = 7.591 μg/ml), 
while the cytotoxicity strength of other ZnO NPs was ZnO 20(+) > ZnO 100(-) > 
ZnO 20(-) in descending order. Additionally, EC50 values of positively charged 
ZnO NPs were higher than those of negatively charged ZnO NPs, suggesting that 
the size and charge of ZnO NPs could affect their cytotoxicity.
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Figure 3. Effect of ZnO NPs and ZnCl2 on the viability of Raw 264.7 cells. Cells were incubated with indicated concentrations of ZnO NPs or ZnCl
20(+), b: ZnO 20(-), c: ZnO 100(+), d: ZnO 100(-), e: ZnCl2), and DMEM media was used as a negative control. Cell 
values are presented as mean ± SEM of the three experiments conducted in duplicate. *p<0.05, **
a b
c d
2 for 24 h (a: ZnO 
viability was then determined by a CCK-8 assay. All 
p<0.001, ***p<0.001 versus control cells incubated with media only.
e
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Table 1. EC50 values (24 h growth inhibition) of ZnO NPs and ZnCl2 on Raw 264.7 cells.
ZnO ZnCl2
(+) 20 nm (-) 20 nm (+) 100 nm (-) 100 nm Neutral
EC50 (μg/ml) 8.434 10.37 7.591 8.627 14.34
95% confidence limit (μg/ml) 7.895-8.973 6.627-14.12 6.716-8.465 7.497-9.846 10.87-17.84
(+): Positive charge. (-): Negative charge. Neutral: No charge.
All values are presented as mean ± SEM of the three experiments conducted in duplicate.
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2.2. Real-time cell viability 
To evaluate the real-time kinetics of ZnO NPs-induced cytotoxicity, the 
impedance-based apparatus (xCelligence) was used to measure cell viability 
during 96 h (Fig. 4). In CCK-8 assay, the positive charged or the bigger sized 
NPs displayed remarkable toxicity in Raw 264.7 cells than the negatively 
charged or the smaller sized one. By contrast, real time assay showed that at the 
concentration of 5 μg/ml, size effect was reverse wherein ZnO (20+/-) were more 
cytotoxic to Raw 264.7 than ZnO (100+/-), whereas at the concentration of 20 
μg/ml size effect was not noticeable. Cytotoxicity of the same charged ZnO NPs 
was more intense at lower concentration than at higher one. Consistent with our 
data in the end point treatment, the positively charged ZnO NPs were more 
cytotoxic to Raw 264.7 cells than the negatively charged one. Consequently, our 
findings indicate that different size and charge of ZnO NPs induce differential 
cytotoxicity against Raw 264.7 cells, suggesting that the size and charge of ZnO 
NPs would affect their cytotoxicity.
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Figure 4. Effect of ZnO NPs on real-time cell viability of Raw 264.7 cells. 
Cells were seeded into E-plate 16 and treated with indicated concentrations of 
ZnO NPs. Real-time cell impedance was monitored every 15-20 min to produce 
time dependent cell response dynamic curves. All values are represented as mean 
± SEM of an experiment conducted in triplicate.
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2.3. ZnO NPs induce the generation of intracellular ROS in Raw 264.7 cells
To investigate whether ZnO NPs could modulate ROS generation, and 
further elucidate the influence of NP size and charge in their toxicity, we treated 
ZnO NPs onto Raw 264.7 cells for the different indicated time points (0.5-1-3-6-
24 h), followed by detecting DCF-DA intracellular ROS (Fig.5). We found that 
20 μg/ml ZnO NPs treatment significantly increased intracellular ROS 
generation in a time-dependent manner: started generating intracellular ROS at 
0.5 h, then peaked at 1 h except ZnO 20(+).  Thereafter, the level of ROS in all 
ZnO NPs group decreased down to the baseline at 6 h. In terms of ROS 
productivity, ZnO 20(+) was most potent: ZnO 20(+) exerted the highest level of 
intracellular ROS generation (~2.5 fold increase) as compared to control after 0.5 
h treatment.  Interestingly, ROS levels of ZnO NPs at 1 h treatment were 
consistent with cell viability data: the bigger sized or the positively charged ZnO 
NPs induced higher level of intracellular ROS than the smaller sized or the 
negatively charged one. However, the size and charge effect of ZnO NPs on the 
ROS generation was unclear at other time points.
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Figure 5. Effect of ZnO NPs on intracellular ROS generation in Raw 264.7 
cells. Cells were incubated with four types of ZnO NPs for different indicated 
times (0.5-1-3-6-24 h), and DMEM media was used as a negative control. Cells 
were then loaded with H2DCF-DA for 15 min, washed twice with NPSS and 
intracellular ROS generation was measured using DTX-880 multimode 
microplate reader. All values are represented as mean ± SEM of the two 
experiments conducted in triplicate, and normalized with control as 100%.
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2.4. Effect of ZnO NPs on mitochondrial membrane potential (MMP)
The above observations suggested that ROS generation induced by ZnO 
NPs might be related to cytotoxicity to Raw 264.7 cells. Next, we addressed 
whether ZnO NP-induced cytotoxicity would be related to mitochondrial 
function. Toward this, we measured the ratio of red/green fluorescence after 3 h 
treatment using JC-1, mitochondrial membrane potential sensor (Fig. 6). Overall, 
treatment with ZnO NPs except ZnO 100(-) significantly dropped the ratio of 
red/green fluorescence compared to control, which indicated the decrement of 
mitochondrial membrane potential (MMP). By contrast, no change in MMP was 
observed in ZnO 100(-) treated cells. Additionally, MMP of the positively 
charged ZnO NP-treated cells was lower than that of the negatively charged one.
.
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Figure 6. Effect of ZnO NPs on mitochondrial membrane potential (MMP) 
in Raw 264.7 cells. Cells were incubated with four types of ZnO NPs for 3 h, 
and DMEM media was used as a negative control. Cells were then loaded with 
JC-1 for 15 min, washed twice by NPSS and MMP was measured using Flex 
Station II384. All values are represented as mean ± SEM of the two experiments 
conducted in triplicate, and normalized with control as 100%. *p<0.05, 
***p<0.001 versus media alone.
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2.5. Effect of ZnO NPs on antioxidant enzyme (SOD, GPx) activity
Superoxide dismutase (SOD) is a group of enzyme known as the first 
defense against oxidative stress. SOD modulates the formation of H2O2 from O2 
•-. 
However, glutathione peroxidase (GPx) transforms H2O2 into water. 
Consequently, the alteration of SOD and GPx could affect ROS activity in both 
cytosol and mitochondria, thus leading to cell death or cell proliferation. To test 
whether ZnO NPs would affect anti-oxidant enzyme activity, ZnO NPs were 
treated onto Raw 264.7 cells for 3 h, followed by measuring the activity of SOD 
and GPx (Fig. 7).We found that SOD activity was reduced when treated with the 
positively charged ZnO NPs (Fig. 7a). Meanwhile, there is no significant size 
effect of ZnO NP on SOD activity. SOD activity was reduced by the positive 
charged ZnO NPs only, albeit barely affected by the negative charged ZnO NP 
treatment. Next, GPx activity was examined. Overall, all ZnO NPs treatment 
decreased GPx activities in Raw 264.7 cells (Fig. 7b). However, the positive 
charged ZnO NPs further decreased GPx activity in Raw 264.7 cells than the 
negative charged one. Taken together, the charge effect is more prominent in 
GPx activity than in SOD activity. Importantly, in terms of enzyme activites, the 
activity of GPx is more correlated to the ROS level rather than SOD. 
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Figure 7. Effect of ZnO NPs on (a) superoxide dismutase (SOD), and (b)
glutathione peroxidase (GPx) activity in Raw 264.7 cells. Cells were 
incubated with four types of ZnO NPs for 3 h, and DMEM media was used as a 
negative control. Cells were then collected and assayed as manufacture’s 
instruction. All values are represented as mean ± SEM of the two experiments 
conducted in triplicate, and normalized with control as 100%. *p<0.05, 
**p<0.01, ***p<0.001 versus media alone.
a
b
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3. In vivo immunotoxicity
3.1. Change of body weight and behavior 
To assess the immunotoxicity in vivo, C57BL/6 mice were orally 
administered with ZnO NPs every day continuously for 14 days. The change of 
relative mouse body weight  gain with time was shown in Figure 8. The positive 
ZnO NP-fed mice experienced a slight weight loss (all less than 10% of body 
weight on the day 0) on the day 5 and 10, then it was recovered on the day 14. 
Specifically, compared to control, the body weight gain of ZnO 20(+)-, and ZnO 
100(+)-fed mice are significant lower at the day 5, 10, and 14 post treatment. By 
contrast, the negative ZnO NPs did not significantly induce body weight loss in 
mice. Nevertheless, none of mice died, and they did not show any alteration in 
behavior during the treatment period.
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Figure 8. Body weight change of mice after ZnO NP administration. Body 
weight was measure on days 0, 5, 10 and 14 after administration of ZnO NPs. 
Day 0 was designated as the day of administration. Values are presented as 
mean ± SEM, n=5.*p<0.05, **p<0.01, ***p<0.001 versus control.
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3.2. Spleen weight, and coefficient of spleen to body weight
After 14 day ZnO NP oral administration, mice were sacrificed, spleens 
were collected and weighed. Spleen weight and the coefficient of spleen to body 
weight were shown in Figure 9. No significant differences of spleen weights 
were noted (Fig. 9a). However, in ZnO 20(+)-fed mice, the coefficients of spleen 
to body weight was significantly higher than control (Fig. 9b). This was 
consistent with the body weight loss induced by ZnO 20(+) as shown in Figure 8.
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Figure 9. Effects of ZnO NPs on spleen weight (a), and coefficient of spleen 
to body weight (b) after 14 day ZnO NP oral administration. Spleen was 
weighed, and coefficient of spleen to body weight was calculated and normalized 
with control as 100%. Values are presented as mean ± SEM, n=5. *p<0.05,
**p<0.01 versus control.
b
a
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3.3. Immunotoxicity parameters
3.3.1. Immunophenotyping
ZnO NP treatment slightly induced the alteration in cell distribution of 
splenocytes (Fig. 10, Tab. 2). While T helper (CD4+) and T cytotoxic (CD8+) 
cells accounted for 16.6% and 9.1%, respectively of the control, the distribution 
of T helper and T cytotoxic cells in splenocytes of treated groups (ZnO 20 (+/-), 
ZnO 100 (+/-)) was changed to 14.66/9.18%, 15.44/11.62%, 14.53/10.22%, 
16.80/11.60%, respectively. Notably, the percentage of T helper cells was 
significantly reduced when treated with ZnO 100(+) as compared to control (Fig. 
10a, Tab. 2). Moreover, the ratio of CD4+ T cells to CD8+ T cells, which are 
subpopulations of T cells (T helper cells and T cytotoxic cells), significantly 
changed from 1.634 fold to 1.301 fold in ZnO 100(+)-fed mice. However, little 
differences were noted in the proportion of B cell, NK cell, and monocyte 
subpopulations. 
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Figure 10. Distribution of leukocytes from spleen after ZnO NPs oral administration for 14 days.
labeled CD4, CD8, CD19, B220, CD16, CD14, CD11 antibodies to identify subpopulations, washed to remove excess antibody and analyzed by flow
by gating on 10,000 events, (a) T cell subpopulation, (b) B cell subpopulation, (c) NK cell subpopulation, (d) Monocyte subpo
a
b
c
d
Control ZnO 20(+) ZnO 20(-)
Splenocytes were isolated, then the cell mixture was stained with fluorescently 
-cytometry. Data were obtained 
pulation distribution in the splenocytes.
ZnO 100(+) ZnO 100(-)
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Table 2. Immunophenotype of splenocytes in C57BL/6 mice administered with 
ZnO NPs for 14 days
Administration PBS ZnO 20(+) ZnO 20(-) ZnO 100(+) ZnO 100(-)
aCD4+CD8- 16.60 ± 0.60 14.66 ± 0.80 15.44 ± 0.54 14.53 ± 1.37* 16.80 ± 0.69
bCD4-CD8+ 9.10 ± 1.18 9.18 ± 0.42 11.62 ± 0.53 10.22 ± 0.64 11.60 ± 0.33
CD4+CD8+ 0.4 ± 0.04 0.32 ± 0.04 0.32 ± 0.04 0.38 ± 0.11 0.28 ± 0.05
B220+ CD19- 0.78 ± 0.09 0.68 ± 0.04 0.80 ± 0.07 0.83 ± 0.09 0.60 ± 0.03
B220-CD19+ 8.70 ± 1.09 7.82 ± 0.38 7.20 ± 0.42 9.02 ± 1.32 5.98 ± 2.23
cB220+ CD19+ 51.58 ± 1.56 51.78 ± 2.52 53.70 ± 0.54 53.50 ± 0.55 52.92 ± 1.04
dCD16+ 58.55 ± 1.30 59.02 ± 2.26 59.88 ± 0.53 55.44 ± 6.69 58.76 ± 1.17
CD11+CD14- 6.80 ± 0.27 6.54 ± 0.22 6.80 ± 0.34 6.52 ± 0.71 5.56 ± 0.23
CD11-CD14+ 0.25 ± 0.03 0.42 ± 0.06 0.26 ± 0.06 0.30 ± 0.03 0.30 ± 0.04
eCD11+CD14+ 1.23 ± 0.06 1.04 ± 0.07 1.04 ± 0.12 1.50 ± 0.21 0.94 ± 0.07
CD4+/CD8+
1.643 ± 
0.07652
1.599 ± 
0.06671
1.338 ± 
0.06395
1.301 ± 
0.07723*
1.450 ± 
0.05374
Values are presented as mean ± SEM, n=5; *p<0.05; a: T helper cells, b: T cytotoxic 
cells, c: B cells, d: Macrophages, e: Monocytes.
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3.3.2. Innate, cell-mediated immune response (DTH and mitogenic response) 
against ZnO NPs
To assess the effect of ZnO NPs on regulation of innate immune response, NK 
cell activity was examined using NK-sensitive YAC-1 target cells. As shown in Table 3, 
a decrease of NK cell activity was observed in the mice treated with ZnO NPs. At the 
ratio of 100:1, ZnO NPs significantly inhibited NK cell activity.
Next, we examined the effect of ZnO NPs on cell-mediated immunity using 
DTH response on C57BL/6 mice. The swelling volume is similar after 24 h and 48 h 
challenge (Tab.  4). An increased DTH response to ZnO NPs was observed. However 
these differences were not statistically significant. Further, we analyzed the mitogen-
stimulated proliferative responses of T and B lymphocytes (Fig. 12). These responses 
were elevated compared to control but not significant. Taken together, ZnO NPs 
affected NK activity but not cell mediated immunity.
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Table 3. NK cell activity in ZnO NP-fed mice.
Effector/Target Ratio
NK cell activity (%; Mean ± SEM)
Control ZnO 20(+) ZnO 20(-) ZnO 100(+) ZnO 100(-)
100:1 10.245 ± 0.698 0 *** 3.335 ± 2.061 *** 0 *** 0 ***
50:1 4.037 ±  0.591 0 * 0.105 ± 0.061 * 1.415 ± 0.930 1.655 ± 1.655
25:1 1.923 ± 1.589 0 0.502 ± 0.435 0 1.263 ± 1.263
YAC-1 cells were used as a target; and effector cells (NK cells) were isolated from the spleen of mice fed with sublethal dose of ZnO NPs 
for 14 days. ZnO NP treatment reduced NK cell cytotoxicity in the treated groups compared to control. Values are presented as mean ± SEM 
of percent (%) cytotoxicity, n=5. *p<0.01, ***p<0.001.
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Table 4. Delayed type hypersensitivity in ZnO NP-primed mice.
Treatment
Foot-pad swelling (mm)
24 h 48 h
Saline ZnO NP Saline ZnO NP
ZnO 20(+) 6.780 ± 1.484 7.242 ± 1.318 6.823 ± 0.3485 7.812 ± 0.7510
ZnO 20(-) 1.523 ± 0.9862 1.202 ± 1.103 1.557 ± 0.3313 1.706 ± 0.5497
ZnO 100(+) 10.55 ± 0.4293 11.70 ± 2.053 7.140 ± 0.6409 10.48 ± 1.521
ZnO 100(-) 4.317 ± 0.8631 4.718 ± 1.730 1.340 ± 0.7702 1.338 ± 0.6657
Measurement of footpad swelling in mice induced by DTH response after 24 h and 48 h challenge. Values are presented as mean ± SEM, 
n=5.
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Figure 11. Mitogenic response of mouse splenocytes. Splenocytes 
(2×106 cells/ml) were incubated for 24 h with concanavalin A (Con A) , or 
lipopolysacchride (LPS) to evaluate T lymphocyte (b) and B lymphocyte (b) 
proliferation, respectively. Values are presented as mean ± SEM, and normalized 
with control as 100%.
a
b
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3.3.3. NO production of splenocytes
NO is a reactive nitrogen which is an important cellular signaling 
molecule involved in several biological processes, moreover serves as one of the 
key mediator of immune defenses. To further explore the impact of ZnO NPs on 
immune defense, we measured the level of splenic NO production after 14 day 
treatment. As shown in Figure 12, a significant decrease in NO level occurred 
after administration of ZnO 20(-), and ZnO 100(+/-). However, there was no 
substantial difference of NO level in ZnO 20(+)-fed mice as compared to the 
control. 
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Figure 12. Nitric oxide (NO) production induced by ZnO NPs in mouse 
splenocytes. Splenocytes were isolated and cultured. The culture supernatant 
was then used to measure nitric oxide (NO) production using Griess reagent. 
Values are presented as mean ± SEM, and normalized with control as 100%. n
=5. **p<0.01, ***p<0.001.
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3.3.4. Serum cytokine level
To explore immune status change induced by ZnO NPs we examined 
serum pro- and anti-inflammatory cytokine (IL-1β, IL-6, TNF-α, IL-12p70, IFN-
γ, and IL-10) level at the end point treatment. We found that overall the level of 
serum cytokines in ZnO-fed mice were lower than saline-fed mice (Fig. 13). In 
particular, serum levels of pro-inflammatory cytokines (IL-1β, TNF-α, and IL-
12p70) in ZnO NP-fed mice were ZnO 20(+) > ZnO 20(-) > ZnO 100(+) > ZnO 
100(-) in descending order. Accordingly, the level of IL-10, an anti-
inflammatory cytokine in ZnO NP-fed mice tended to be significantly lower than 
PBS-fed mice. By contrast, there was no significant change of cytokine level in 
ZnO 20(+)-fed mice. In terms of size and charge effect on serum cytokine level, 
the size and charge were correlated to serum cytokine level. Further, the size 
appears more correlated to the serum cytokine than the charge. Taken together, 
our data show that oral intake of ZnO NPs in mice could drop the level of serum 
cytokines, importantly implying the possible suppression of immune status of 
C57BL/6 mice fed with ZnO NPs.
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Figure 13. Serum cytokine profiles in ZnO NP-fed mice. After 14 day administration, mice were retro-orbital bled, isolated serum by centrifugation and 
the level of IL-1β (a), TNF-α (b), IL-12p70 (c), IFN-γ (d), and IL-10 (e) were examined using Multiplex Bead Array System (Bio-Rad). IL-6 is lower than 
detectable limitation. Values are presented as mean ± SEM, n=5.*p<0.05, **p<0.01, ***p<0.001.
a b
c d e
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IV. DISCUSSION
Convincing evidences showed that ZnO NPs would have a potential to 
deliver to several organ such as liver, spleen, kidneys, brain or heart after 
exposure (Yeh et al. 2012, 085102). In this regard, ZnO NPs accessed in human 
body would interact with immune cell, thus, damaging immune tissues and 
organs. However, the immunotoxicity of ZnO NPs in relation to specifically the 
size and charge of ZnO NP are unclear. To address this issue, we assessed the 
immunotoxicity of ZnO NPs in vitro and in vivo and explored their underlying 
mechanism. First, in vitro study indicates that ZnO NPs induce cytotoxicity to 
immunocytes via ROS generation, which is influenced by the size and charge of 
ZnO NPs. To validate this, we examined cell viability using colorimetric (CCK-8 
assay) and impedance assay (real-time kinetic assay), intracellular ROS 
production, mitochondria membrane potential (MMP), and antioxidant enzyme 
activity (SOD, GPx) in Raw 264.7, macrophage cell line.
Cell viability assays (CCK-8, real-time xCelligence) showed that ZnO 
NPs with different sizes and charges have differential cytotoxicity to Raw 264.7 
cells (Fig. 3). Interestingly, the positively charged NPs exerted higher 
cytotoxicity against Raw 264.7 cells than the negatively charged one. On the 
contrary to static CCK-8 assay, real- time dynamic assay revealed that ZnO NPs 
at the concentration of 5 μg/ml displayed differential cytotoxicity pattern, albeit 
similar at higher concentrations (10-20 μg/ml) (Fig. 4). ZnO NP-induced 
cytotoxicity could be affected by the release of Zn2+ ions through the dissolution 
of ZnO NPs within aqueous culture media (Cho et al. 2011, 27, George et al. 
2010, 15-29, Xia et al. 2008, 2121-34). Hence, a control experiment was 
performed with ZnCl2. In term of EC50, we found that ZnO NPs would cause 
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cytotoxicity at lower dose compared to ZnCl2 (Tab. 1). This difference might be 
due to inherent features of metal oxides: free Zn2+ ions, and oxidative radical-
generated oxide, and ZnO NP surface charge would synergistically exert 
cytotoxicity to eukaryotic cells. 
Next, we checked ROS production to uncover the mechanism of ZnO
NP-induced cytotoxicity. ZnO NPs have been shown to generate the formation of 
ROS (Song et al. 2010, 389-97, Xia et al. 2008, 2121-34), which is the major 
molecule to exert the cytotoxicity to biologic cells. Since ZnO NPs were 
dispersed in aqueous solution, their active sites could interact with water or 
oxygen to generate ROS, such as superoxide anions, hydroxyl radicals, and 
singlet oxygen, thereby resulting in cell stress or even cell death. In that context, 
we hypothesized that ZnO NPs would induce cell stress by way of generating 
ROS. For this, intracellular ROS production was examined at the indicated time 
points (0.5-1-3-6-24 h). We found that the intracellular ROS production induced 
by ZnO NPs is time-dependent (Fig. 5). For instance, ZnO NPs at higher 
concentration induced higher level of intracellular ROS at short treatment time 
(< 6 h), albeit almost same levels to control after 6 h. Long time (> 6 h) 
incubation would increase the reagglomeration of ZnO NPs, eventually, 
decreasing cytotoxicity. Importantly, we found that the positively charged ZnO 
NPs exhibited higher level of intracellular ROS generation than the negatively 
charged one. 
Since the production of ROS has been shown to disrupt the MMP 
enough to induce apoptosis (Curtin, Donovan, and Cotter 2002, 49-72, Orrenius, 
Gogvadze, and Zhivotovsky 2007, 143-83), we assessed the impact of ZnO NPs 
on the MMP (Fig. 6). Following exposure to the negative charge 100 nm ZnO, 
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there was no change in the MMP when compared to control cells. By contrast, a 
significant alteration in the MMP was observed following exposure to the ZnO 
20(+/-) and ZnO 100(+). There is no correlation between the production of ROS 
elicited by all four types of ZnO NPs and their MMP patterns. This discrepancy 
might be ascribed to unique cell death mechanism of every ZnO NPs irrespective 
of the size and charge. For instance, since ZnO NPs might accumulate outside 
the mitochondria, their surface charges would affect the charge on the outer 
portion of the mitochondrial membrane, leading to an imbalance in the MMP. 
Last, to assess oxidative stress parameters we examined the antioxidant 
enzyme activities (SOD, GPx) induced by ZnO NPs (Fig. 8). Overall, all ZnO 
NPs treatment decreased both SOD and GPx activities of Raw 264.7 cells. SOD 
is a defense enzyme against the harmful effect of ROS, which converts O2 
•- into 
H2O2, thereafter H2O2 can be degraded into H2O by GPx (Valko et al. 2007, 44-
84). The generation of ROS, specifically O2 
•- can damage mitochondrial, thus 
resulting in mitochondrial dysfunction (Kirkinezos, and Moraes 2001, 449-57). 
This decreased enzymes (SOD, GPx) activities might be owing to the generation 
of ROS in cells induced by ZnO NPs. Of note, in terms of enzyme activity, the 
activity of GPx is more correlated to the ROS level rather than SOD. 
In this experiment, another merit is the validity of in vitro
immunotoxicity test using Raw 264.7 cell line. While, this cell line is well-
known standard cell line for in vitro immunotoxicity test, in vitro
immunotoxicity test for nanoparticle is not established. Using this cell line, we 
verified the potential value of in vitro immunotoxicity battery for unknown 
nanoparticle, since the in vitro data might be compatible to in vivo
immunotoxicity profiles. Collectively, our in vitro data clearly indicates that 
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different sized- and charged-ZnO NPs induce differential cytotoxicity against 
Raw 264.7 cells via ROS generation, MMP reduction, and anti-oxidant activity
decrement. Further, we confirmed that the size and charge of ZnO NPs could 
affect their cytotoxicity. 
Since, in vitro culture cannot reflect the complexity of an in vivo system, 
which is preferred for the toxicological evaluation; next, we examined the 
immunotoxicologic parameters induced by oral intake of ZnO NPs in mice. Our 
in vivo study indicates that the different sized- and charged-ZnO NPs could cause 
immunotoxicity in ZnO NP-fed mice, of which nature is a minor 
immunosuppression. This stems from our immunotoxicological data. Prior to 
immunotoxicological evaluation, we checked the weight-related parameters 
(body weight, spleen weight, and coefficient of spleen to body weight).  Of these, 
only the reduced body weight gain was noted, suggesting the potential ZnO NP 
immunotoxicity in vivo. Since in vitro data showed ZnO-induced toxicity in 
immunocytes, body weight change coupled with in vitro data might be 
considered for predicting potential immunotoxicity of nanoparticles. 
Next, to explore the effect of ZnO NPs on the cellular mediated 
immunity(CMI), we measured the delayed-type hypersensitivity (DTH) reaction 
to ZnO NPs, splenocyte proliferation in response to Con A and LPS, NK cell 
activity, and splenocyte phenotyping. Overall, no significant change was 
observed in DTH responses (Tab. 4), T and B cell proliferation (Fig. 11). By 
contrast, we found the slight change in splenocyte phenotypes (Fig. 10, Tab. 2). 
Since CD4+ cells can help the proliferation and differentiation of other T and B 
cells, and CD8+ cells can exert cytotoxicity, and regulate CD4+ cells, the ratio of 
CD4+/CD8+ can reflect the overall immune status in host. Of note, there was the 
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decreased percentage of CD4+ T cell subpopulation in ZnO 100(+)-fed mice as 
compared to control mice (Fig. 10a). Consistently, the ratio of CD4+/CD8+ was 
reduced, which might imply systemic immune suppression. These CMI variables 
do not tell specific function of innate arm in CMI. Toward this, we checked NK 
activity. Astonishingly, NK cell activity at the ratio of 100:1 was significantly 
decreased in all ZnO NP-fed mice compared to control (Tab. 3). NK cells were 
defined as lymphocytes mediating cytotoxicity against certain tumors and virus-
infected target cells. In this point, the suppression of NK cell activity may reveal 
the weakened innate defense in CMI, consequently getting vulnerable to 
opportunistic dangers such as infection, cancer, and stress. Given this, we 
hypothesized that if these data would be valid, humoral immune mediators 
should be co-regulated toward the immune suppression. To verify this, we 
selected two humoral immune parameters (nitric oxide, cytokines). 
First, we checked NO production from splenocytes of ZnO NP-fed mice.
Nitric oxide (NO) is a reactive nitrogen species which plays an important role in 
destruction and suppression of many intracellular pathogenic organisms (Green 
et al. 1994, 87-94, Guzik, Korbut, and Adamek-Guzik 2003, 469-87). NO act as 
an effector molecule in macrophage-mediated cytotoxicity (Holan et al. 2002, 
989-95). However the NO production of macrophage was regulated and required 
to be optimized by CD4+ T cells. We found that three oral intake of ZnO NPs 
except ZnO 20(+) significantly decreased NO production of splenocytes (Fig. 
12). Viewed together, this is in line with the suppression of NK activity and the 
ratio of CD4+/CD8+ observed.
Since, NO could contribute to the regulation of immune reaction by 
modifying the release of cytokines (Marcinkiewicz, and Chain 1993, 146-50, 
49
Schwentker et al. 2002, 1-10, Tavares Murta et al. 1999, 87-92), finally we 
quantified the serum cytokine release in ZnO-fed mice. To further analyze the 
several facets of in vivo immunotoxicity in ZnO NP-fed mice, we selected six 
kinds of pro- and anti-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-12p70, 
IFN-γ, and IL-10). Cytokine assay showed that that overall the level of serum 
cytokines in ZnO-fed mice were decreased as compared to control (Fig. 13). Of 
these cytokines, in light of the concentration serum, IL-1β, and IL-10 were 
prominent in detecting the cytokine change in ZnO NP-fed mice. These 
cytokines were the representative pro- and anti-inflammatory cytokine, 
respectively. The decreased level of these opposite cytokines in ZnO NP-fed 
mice might be ascribed to nonspecific immune suppression or even imbalance 
between pro- and anti-inflammatory cytokine network. The limitation in this 
study is the lack of different dose usage in vivo. To gauge this phenomena in 
detail, further work will be needed. 
Synthesizing these immunotoxicological data in vivo and in vitro, our 
results indicate that different sized- and charged-ZnO NPs would cause in vitro
and in vivo immunotoxicity, of which nature is a minor immunosuppression.
This has important implications for individuals who may be chronically exposed 
to ZnO NPs. Further, this study offered the possibility of the new immune 
parameters such as cytokine and NO for gauging immunotoxicity for 
nanoparticles.
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